Clinical Applications of Immuno-PET in Lymphoma: A Systematic Review
<b>Objective:</b> Immuno-positron emission tomography (iPET) combines the sensitivity of the PET imaging technique and the targeting specificity of radio-labelled monoclonal antibodies (mAb). Its first clinical applications in humans were described in the late 1990s, and several patholog...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-07-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/14/3488 |
| _version_ | 1797407107172007936 |
|---|---|
| author | Elizabeth Katherine Anna Triumbari David Morland Riccardo Laudicella Matteo Bauckneht Domenico Albano Salvatore Annunziata |
| author_facet | Elizabeth Katherine Anna Triumbari David Morland Riccardo Laudicella Matteo Bauckneht Domenico Albano Salvatore Annunziata |
| author_sort | Elizabeth Katherine Anna Triumbari |
| collection | DOAJ |
| description | <b>Objective:</b> Immuno-positron emission tomography (iPET) combines the sensitivity of the PET imaging technique and the targeting specificity of radio-labelled monoclonal antibodies (mAb). Its first clinical applications in humans were described in the late 1990s, and several pathologies have benefitted from this molecular imaging modality since then. Our scope was to assess current clinical applications of immuno-PET in patients with lymphoma. Therefore, a systematic review of the published literature was performed. <b>Methods:</b> PubMed/Medline and Scopus databases were independently searched by two nuclear medicine physicians, to identify studies describing the clinical use of immuno-PET in patients with lymphoma. Methodological quality of the included articles was assessed by using the Quality Assessment of Diagnostic Accuracy Studies criteria. The studies were then analyzed concerning the molecular target of interest. <b>Results:</b> The initial search yielded 1407 articles. After elimination of duplicates, 1339 titles/abstracts were evaluated. Only two articles were found to comply with the inclusion criteria and two more were found during the cross-reference check. Among the four included articles, three described the use of <sup>89</sup>Zr-labelled antibodies targeting CD20+ relapsed/refractory B-cell lymphomas and one concerned the use of <sup>68</sup>Ga-labelled mAb targeting CXCR4 in patients with non-Hodgkin lymphomas. <b>Conclusions:</b> Very limited literature data are currently available on the clinical use of iPET in patients with lymphoma. This technique is encountering obstacles in its wider use, possibly because of the need of specific facilities, unfavorable dosimetry, and unclear correlation of immuno-tracer biodistribution with patients’ clinical and tumors’ molecular characteristics. However, iPET may represent a useful tool to non-invasively visualize the heterogenous individual immunological environment, thus potentially guiding treatment-planning in lymphoma patients, and hence deserves further exploitation. |
| first_indexed | 2024-03-09T03:36:28Z |
| format | Article |
| id | doaj.art-67fa8fd3ff9e406392f7e2d865a80fc5 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T03:36:28Z |
| publishDate | 2022-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-67fa8fd3ff9e406392f7e2d865a80fc52023-12-03T14:48:03ZengMDPI AGCancers2072-66942022-07-011414348810.3390/cancers14143488Clinical Applications of Immuno-PET in Lymphoma: A Systematic ReviewElizabeth Katherine Anna Triumbari0David Morland1Riccardo Laudicella2Matteo Bauckneht3Domenico Albano4Salvatore Annunziata5Unità di Medicina Nucleare, TracerGLab, Dipartimento di Radiologia, Radioterapia ed Ematologia, Fondazione Policlinico Universitario A. Gemelli, IRCCS, 00168 Rome, ItalyUnità di Medicina Nucleare, TracerGLab, Dipartimento di Radiologia, Radioterapia ed Ematologia, Fondazione Policlinico Universitario A. Gemelli, IRCCS, 00168 Rome, ItalyDepartment of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, via Consolare Valeria n1, 98125 Messina, ItalyDepartment of Health Sciences (DISSAL), University of Genova, 16132 Genova, ItalyNuclear Medicine, ASST SpedaliCivili Brescia, 25122 Brescia, ItalyUnità di Medicina Nucleare, TracerGLab, Dipartimento di Radiologia, Radioterapia ed Ematologia, Fondazione Policlinico Universitario A. Gemelli, IRCCS, 00168 Rome, Italy<b>Objective:</b> Immuno-positron emission tomography (iPET) combines the sensitivity of the PET imaging technique and the targeting specificity of radio-labelled monoclonal antibodies (mAb). Its first clinical applications in humans were described in the late 1990s, and several pathologies have benefitted from this molecular imaging modality since then. Our scope was to assess current clinical applications of immuno-PET in patients with lymphoma. Therefore, a systematic review of the published literature was performed. <b>Methods:</b> PubMed/Medline and Scopus databases were independently searched by two nuclear medicine physicians, to identify studies describing the clinical use of immuno-PET in patients with lymphoma. Methodological quality of the included articles was assessed by using the Quality Assessment of Diagnostic Accuracy Studies criteria. The studies were then analyzed concerning the molecular target of interest. <b>Results:</b> The initial search yielded 1407 articles. After elimination of duplicates, 1339 titles/abstracts were evaluated. Only two articles were found to comply with the inclusion criteria and two more were found during the cross-reference check. Among the four included articles, three described the use of <sup>89</sup>Zr-labelled antibodies targeting CD20+ relapsed/refractory B-cell lymphomas and one concerned the use of <sup>68</sup>Ga-labelled mAb targeting CXCR4 in patients with non-Hodgkin lymphomas. <b>Conclusions:</b> Very limited literature data are currently available on the clinical use of iPET in patients with lymphoma. This technique is encountering obstacles in its wider use, possibly because of the need of specific facilities, unfavorable dosimetry, and unclear correlation of immuno-tracer biodistribution with patients’ clinical and tumors’ molecular characteristics. However, iPET may represent a useful tool to non-invasively visualize the heterogenous individual immunological environment, thus potentially guiding treatment-planning in lymphoma patients, and hence deserves further exploitation.https://www.mdpi.com/2072-6694/14/14/3488immuno-PETlymphomasystematic reviewhuman<sup>89</sup>Zr<sup>68</sup>Ga-pentixafor |
| spellingShingle | Elizabeth Katherine Anna Triumbari David Morland Riccardo Laudicella Matteo Bauckneht Domenico Albano Salvatore Annunziata Clinical Applications of Immuno-PET in Lymphoma: A Systematic Review Cancers immuno-PET lymphoma systematic review human <sup>89</sup>Zr <sup>68</sup>Ga-pentixafor |
| title | Clinical Applications of Immuno-PET in Lymphoma: A Systematic Review |
| title_full | Clinical Applications of Immuno-PET in Lymphoma: A Systematic Review |
| title_fullStr | Clinical Applications of Immuno-PET in Lymphoma: A Systematic Review |
| title_full_unstemmed | Clinical Applications of Immuno-PET in Lymphoma: A Systematic Review |
| title_short | Clinical Applications of Immuno-PET in Lymphoma: A Systematic Review |
| title_sort | clinical applications of immuno pet in lymphoma a systematic review |
| topic | immuno-PET lymphoma systematic review human <sup>89</sup>Zr <sup>68</sup>Ga-pentixafor |
| url | https://www.mdpi.com/2072-6694/14/14/3488 |
| work_keys_str_mv | AT elizabethkatherineannatriumbari clinicalapplicationsofimmunopetinlymphomaasystematicreview AT davidmorland clinicalapplicationsofimmunopetinlymphomaasystematicreview AT riccardolaudicella clinicalapplicationsofimmunopetinlymphomaasystematicreview AT matteobauckneht clinicalapplicationsofimmunopetinlymphomaasystematicreview AT domenicoalbano clinicalapplicationsofimmunopetinlymphomaasystematicreview AT salvatoreannunziata clinicalapplicationsofimmunopetinlymphomaasystematicreview |